Heidelberg Pharma AG (ETR:HPHA)

PRESS RELEASE

published on 10/01/2024 at 17:29, 1 year 9 months ago

Heidelberg Pharma: New Clinical Data on Lead ADC Candidate HDP-101 Presented at IMS 2024 Demonstrating Complete Remission in One Patient
Heidelberg Pharma presents new clinical data on lead ADC candidate HDP-101 at IMS 2024, showing complete remission in one patient. Company developing innovative ADCs for cancer treatment

Clinical Data Heidelberg Pharma ADC IMS 2024 Complete Remission
BRIEF

published on 10/01/2024 at 15:32, 1 year 9 months ago

Heidelberg Pharma AG Announces Updated Financial Guidance

Financial Year 2024 Heidelberg Pharma Operating Expenses Updated Guidance Cash Requirements
BRIEF

published on 10/01/2024 at 15:32, 1 year 9 months ago

Heidelberg Pharma AG annonce une mise à jour de ses prévisions financières

Heidelberg Pharma Orientations Mises À Jour Dépenses D'exploitation Exercice Financier 2024 Besoins En Liquidités
PRESS RELEASE

published on 10/01/2024 at 15:27, 1 year 9 months ago

EQS-Adhoc: Heidelberg Pharma AG Announces Updated Guidance
Heidelberg Pharma AG adjusts its 2024 guidance, expecting sales and other income between EUR 10.0 - 12.0 million and operating expenses between EUR 30.0 - 33.0 million. The company anticipates secured financing until mid-2025

Financial Year Heidelberg Pharma AG Operating Expenses Updated Guidance Secured Financing
BRIEF

published on 09/23/2024 at 13:10, 1 year 9 months ago

Heidelberg Pharma to Present New Clinical Data on HDP-101 at IMS 2024

Clinical Data Heidelberg Pharma HDP-101 Multiple Myeloma IMS 2024
BRIEF

published on 09/23/2024 at 13:10, 1 year 9 months ago

Heidelberg Pharma présentera de nouvelles données cliniques sur HDP-101 à l'IMS 2024

Heidelberg Pharma HDP-101 Myélome Multiple Données Cliniques IMS 2024
PRESS RELEASE

published on 09/23/2024 at 13:05, 1 year 9 months ago

Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to be Presented at International Myeloma Society Annual Meeting 2024
Heidelberg Pharma announces new clinical data on lead ATAC candidate HDP-101 to be presented at International Myeloma Society Annual Meeting 2024

Clinical Data Heidelberg Pharma HDP-101 ATAC Candidate Myeloma Society
BRIEF

published on 07/11/2024 at 07:10, 2 years ago

Heidelberg Pharma Reports on First Half-Year 2024 and the Course of Business

Financial Results Clinical Trial Heidelberg Pharma HDP-101 Multiple Myeloma
BRIEF

published on 07/11/2024 at 07:10, 2 years ago

Heidelberg Pharma rend compte du premier semestre 2024 et de la marche des affaires

Résultats Financiers Essai Clinique Heidelberg Pharma HDP-101 Myélome Multiple
PRESS RELEASE

published on 07/11/2024 at 07:05, 2 years ago

Heidelberg Pharma Reports on First Half-Year 2024 and the Course of Business
Heidelberg Pharma AG reports positive preliminary efficacy data for HDP-101 in multiple myeloma clinical trial. Key events include AACR Meeting presentation & FDA Orphan Drug Designation

Clinical Trial HDP-101 Heidelberg Pharma AG AACR Meeting FDA Orphan Drug Designation

Published on 07/14/2026 at 11:30, 40 minutes ago

FireFox Gold Expands Drill Program at Mustajärvi and Commences Drilling at the Sarvi Project in Lapland, Finland
Published on 07/14/2026 at 01:45, 10 hours 25 minutes ago

Arctic Fox Lithium Approved for Trading on the OTCQB Venture Market and Announces DTC Eligibility
Published on 07/14/2026 at 00:01, 12 hours 9 minutes ago

Captor Capital Announces Delay in its Annual Filings
Published on 07/13/2026 at 23:10, 13 hours ago

Galaxy Ventures Inc. Announces Director Resignation
Published on 07/13/2026 at 21:35, 14 hours 35 minutes ago

ATHA Energy Announces Corporate Activities Update

View all ACCESSWIRE

Published on 07/14/2026 at 12:05, 5 minutes ago

ACCESS TO RENEWABLE ENERGY CRITICAL TO KEEP MOBILE INDUSTRY ON TRACK FOR NET ZERO, NEW GSMA REPORT FINDS
Published on 07/14/2026 at 11:20, 50 minutes ago

Turkiye Garanti Bankasi A.S.: Announcement regarding Corporate Governance Rating Agreement
Published on 07/14/2026 at 11:05, 1 hour 5 minutes ago

Newronika Receives CE Mark for αDBS®, Advancing Its Mission to Make Adaptive Therapy the Standard of Care
Published on 07/14/2026 at 11:05, 1 hour 5 minutes ago

Yilu Liu, Yushan Yan, Johann W. Kolar have been chosen as laureates of Global Energy Prize 2026
Published on 07/14/2026 at 11:00, 1 hour 10 minutes ago

Growth financing: SIXT places EUR 500 million bond – order book more than three times oversubscribed

View all EQS

Published on 07/13/2026 at 18:00, 18 hours 10 minutes ago

CP Icade - Icade reprend 100% de la propriété de la Tour Eqho à la Défense
Published on 07/13/2026 at 18:00, 18 hours 10 minutes ago

PR Icade - Icade regains full ownership of the Eqho Tower in La Défense
Published on 07/13/2026 at 18:00, 18 hours 10 minutes ago

THERMADOR GROUPE : 2026 half-year turnover
Published on 07/13/2026 at 18:00, 18 hours 10 minutes ago

THERMADOR GROUPE : publication du chiffre d'affaires semestriel 2026
Published on 07/13/2026 at 17:45, 18 hours 25 minutes ago

Weekly share buyback

View all LES ECHOS COMFI WIRE

News